olanzapine fluoxetine
Antipsychotic • Brands: Symbyax
Last reviewed: 2025-12-30
General information
- Class: Antipsychotic
- Common US brands: Symbyax
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Fixed-dose combination of olanzapine (second-generation antipsychotic; D2/5-HT2A antagonism) and fluoxetine (SSRI). Indicated for bipolar I depression and treatment-resistant depression (label).
Metabolism & Half‑life
- Metabolism: CYP1A2 (olanzapine), UGT1A4 (olanzapine), CYP2D6 (fluoxetine; and minor olanzapine pathway)
- Half‑life: Single-dose mean 30 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Olanzapine and fluoxetine capsules prescribing information — DailyMed (2025)
- Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression — Archives of General Psychiatry (2003)
- The CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)
- APA Clinical Practice Guideline for the Treatment of Depression — American Psychiatric Association (2023)
- CANMAT 2024 Clinical Guidelines for Major Depressive Disorder — Canadian Journal of Psychiatry (2024)